Stockscreener 앱 받기
17.98
6.99%
-1.392
전일 마감가:
$19.37
열려 있는:
$19.22
하루 거래량:
100.19K
Relative Volume:
0.52
시가총액:
$963.56M
수익:
-
순이익/손실:
-
주가수익비율:
-24.98
EPS:
-0.7198
순현금흐름:
-
1주 성능:
-17.05%
1개월 성능:
+9.59%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$17.99
$19.90
1주일 범위
$17.99
$22.07
52주 변동 폭
$14.85
$22.98
Seaport Therapeutics Inc Stock (SPTX) Company Profile
명칭
Seaport Therapeutics Inc
전화
617-807-4062
주소
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
18.00 | 1.04B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc 주식(SPTX)의 최신 뉴스
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart - mexc.co
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Insider Stock Purchases: June 24, 2026 - Moomoo
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - marketscreener.com
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com India
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
Seaport Therapeutics reports phase 1 data for anxiety drug By Investing.com - Investing.com South Africa
Seaport Therapeutics 1Q 2026: Net loss $(25.4M), EPS $(10.34) — 10-Q Summary - TradingView
Seaport Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
SPTX: Q1 2026 net loss rose to $25.4M; cash and investments total $212.6M post-IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, vs. FactSet Est of $10.64 Loss - marketscreener.com
Seaport Therapeutics reports phase 1 data for anxiety drug - Investing.com
SPTX: Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment - TradingView
Seaport Therapeutics reports Q1 2026 net loss of $25.4M, cash $212.6M before $260M IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, Vs. FactSet Est of $10.64 Loss - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers - TradingView
Press Release: Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - The Joplin Globe
Seaport Therapeutics Inc (SPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Seaport Therapeutics Inc 주식 (SPTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
1.21%
3.14%
자본화:
|
볼륨(24시간):